Compare DexCom, Inc. (DXCM) vs Altria Group Inc (MO) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
DexCom, Inc. vs Altria Group Inc — how do they compare? DexCom, Inc. trades at $77.69 (market cap $28.06B), while Altria Group Inc trades at $72.28 (market cap $117.76B). The key difference: Altria Group Inc is far larger — about 4.2× DexCom, Inc.'s market cap, and Altria Group Inc pays a 6.01% dividend while DexCom, Inc. pays none. Which is the better fit depends on your goals.
| DXCM | MO | |
|---|---|---|
Market Cap | $28.06B | $117.76B |
Sector | Health | Consumer Staples |
52-Week High | $89.53 | $74.55 |
52-Week Low | $54.84 | $54.72 |
Enterprise Value | $27.03B | $138.83B |
Dividend Yield | — | 6.01% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
DexCom (DXCM) trades at $74.12, down 2.92% on the day, with a bullish technical signal from moving averages. The company demonstrates strong fundamentals with consistent revenue growth, expanding profit margins, and a track record of beating earnings estimates. Recent regulatory approvals for its G7 15-day CGM in Canada and pediatric clearance for its Stelo OTC system in the U.S. highlight ongoing product expansion.
The investment thesis centers on DexCom's leadership in the growing CGM market, supported by strong financial execution and analyst optimism. Key risks include competition from Abbott, the commercial unproven nature of expansion into non-insulin Type 2 diabetes patients, and potential disruption from GLP-1 drug adoption. The consensus price target of $84.33 suggests ~14% upside from current levels.
MO trades at $70.18, down 2.35% today, with a bearish technical signal but strong fundamentals including a 39.52% net margin and consistent dividend payments. Recent earnings beat expectations in Q1 2026, while Q2 2026 estimates are $1.50 EPS. The stock holds a P/E of 14.72 and robust cash flow from operations of $9.29B in 2025, supporting its status as a Dividend King with over 50 years of increases.
Outlook remains stable due to high profitability and defensive appeal, but risks include declining smoking trends and regulatory pressures. Analysts are bullish with a $71.00 consensus target, offering a potential upside from current levels amid market volatility.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About DexCom, Inc.
Dexcom designs and commercializes continuous glucose monitoring systems for diabetics. CGM systems serve as an alternative to the traditional blood glucose meter process, and the company is evolving its CGM systems to include the disposable sensor and the durable receiver.
Read more on DXCM →About Altria Group Inc
Altria comprises Philip Morris USA, U.S. Smokeless Tobacco, John Middleton, Helix Innovations, and Philip Morris Capital, although the company plans to wind down Philip Morris Capital by the end of 2022. It holds a 10% interest in the world's largest brewer, Anheuser-Busch InBev. Through its tobacco subsidiaries, Altria holds the leading position in cigarettes and smokeless tobacco in the United States and the number-two spot in machine-made cigars. The company's Marlboro brand is the leading cigarette brand in the U.S. with a 43% share in 2020. Altria holds strategic investments in JUUL Labs (35% economic interest) and Cronos (42%).
Read more on MO →
